Catalent Insiders
Catalent employs about 17 K people. The company is managed by 40 executives with a total tenure of roughly 179 years, averaging almost 4.0 years of service per executive, having 425.0 employees per reported executive. Breaking down Catalent's management performance can provide insight into the firm performance.
| John Chiminski Chairman Chairman of the Board, Chief Executive Officer |
| Steven Fasman President Senior Vice President General Counsel and Corporate Secretary |
Catalent |
Catalent Management Team Effectiveness
Catalent's management efficiency ratios could be used to measure how well Catalent manages its routine affairs as well as how well it operates its assets and liabilities.Catalent Workforce Comparison
Catalent is rated third in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 156,100. Catalent retains roughly 17,000 in number of employees claiming about 11% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.09) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.07) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.07. Catalent Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Catalent insiders, such as employees or executives, is commonly permitted as long as it does not rely on Catalent's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Catalent insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Michael Grippo over three months ago Disposition of 1114 shares by Michael Grippo of Catalent subject to Rule 16b-3 | ||
Ryan Michelle R over three months ago Disposition of 2800 shares by Ryan Michelle R of Catalent at 59.7 subject to Rule 16b-3 | ||
Jonathan Arnold over three months ago Acquisition by Jonathan Arnold of tradable shares of Catalent subject to Rule 16b-3 | ||
Jack Stahl over three months ago Acquisition by Jack Stahl of 4663 shares of Catalent subject to Rule 16b-3 | ||
Charles Lickfold over three months ago Disposition of 637 shares by Charles Lickfold of Catalent subject to Rule 16b-3 | ||
Matti Masanovich over six months ago Disposition of 2993 shares by Matti Masanovich of Catalent at 56.74 subject to Rule 16b-3 | ||
Aristippos Gennadios over six months ago Disposition of 349 shares by Aristippos Gennadios of Catalent at 58.7 subject to Rule 16b-3 | ||
Aristippos Gennadios over six months ago Acquisition by Aristippos Gennadios of 18746 shares of Catalent subject to Rule 16b-3 |
Catalent Notable Stakeholders
A Catalent stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Catalent often face trade-offs trying to please all of them. Catalent's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Catalent's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| John Chiminski | Chairman of the Board, Chief Executive Officer | Profile | |
| Tom PEng | President Delivery | Profile | |
| Trish Hunt | President Health | Profile | |
| Steven Fasman | Senior Vice President General Counsel and Corporate Secretary | Profile | |
| Jonathan Arnold | President - Oral & Specialty Delivery | Profile | |
| Ricky Hopson | Division President | Profile | |
| Scott Gunther | Senior Vice President - Quality & Regulatory Affairs | Profile | |
| Wetteny Joseph | Chief Financial Officer, Senior Vice President | Profile | |
| Alessandro Maselli | Senior Vice President - Global Operations | Profile | |
| Charles Lickfold | Senior Vice President, Chief Information Officer | Profile | |
| Aristippos Gennadios | President - Softgel & Oral Technologies | Profile | |
| Ricardo Pravda | Chief Human Resource Officer, Senior Vice President | Profile | |
| Matti Masanovich | Senior CFO | Profile | |
| Peter Zippelius | Independent Director | Profile | |
| Donald Morel | Independent Director | Profile | |
| John Greisch | Independent Director | Profile | |
| Gregory Lucier | Independent Director | Profile | |
| Rolf Classon | Independent Director | Profile | |
| Michael Barber | Independent Director | Profile | |
| Christa Kreuzburg | Independent Director | Profile | |
| Madhavan Balachandran | Independent Director | Profile | |
| Jack Stahl | Lead Independent Director | Profile | |
| Rosemary Crane | Independent Director | Profile | |
| Thomas Castellano | VP of Fin. and Investor Relations and Treasurer | Profile | |
| Joseph JD | General VP | Profile | |
| Michael Hatzfeld | VP Officer | Profile | |
| Paul Surdez | Vice Relations | Profile | |
| David McErlane | Group Segment | Profile | |
| Kay Schmidt | Senior Vice President - Technical Operations | Profile | |
| Karen Santiago | VP Office | Profile | |
| John MBA | Executive Board | Profile | |
| Steven Esq | Corp VP | Profile | |
| Karen Flynn | President - Biologics and Chief Commercial Officer | Profile | |
| Michael Grippo | Senior Vice President - Strategy and Corporate Development | Profile | |
| Julien Meissonnier | VP Officer | Profile | |
| Lisa Evoli | Senior Officer | Profile | |
| J Carroll | Independent Director | Profile | |
| Dejan Lamesic | Head Development | Profile | |
| Ricci Whitlow | President - Clinical Supply Services | Profile | |
| Z Mahdavi | Vice President of Open Innovation, Biologics, Cell and Gene Therapy | Profile |
Catalent Workforce Analysis
Traditionally, organizations such as Catalent use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Catalent within its industry.Catalent Manpower Efficiency
Return on Catalent Manpower
| Revenue Per Employee | 257.7K | |
| Revenue Per Executive | 109.5M | |
| Net Loss Per Employee | 61.4K | |
| Net Loss Per Executive | 26.1M | |
| Working Capital Per Employee | 92.1K | |
| Working Capital Per Executive | 39.1M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Catalent Stock
If you are still planning to invest in Catalent check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Catalent's history and understand the potential risks before investing.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |